Celdara Medical, LLC today announced that the National Institute of Allergy and Infectious Disease of the National Institutes of Health (NIH) has awarded a three-year Small Business Innovation Research (SBIR) Fast-Track award to fund the company’s advancement of CM-IAV1, a human monoclonal antibody to treat and prevent both group 1 and group 2 influenza A viruses, including H5N1 strains similar to the currently circulating avian influenza virus.
Dr. Jake Reder, Co-founder and Chief Executive Officer of Celdara Medical, remarked, “We are grateful to the NIAID for their support of this important program. While pandemic fatigue affects us all, so do pandemics. With highly pathogenic avian influenza currently present in 29 states, as well as Canada, Europe, the Middle East, Africa, and Asia, and case fatality rates orders of magnitude higher than SARS-CoV-2, it is crucial that we develop mitigations against pandemic influenza well in advance of their need. This work will move us multiple steps forward toward that worthy goal.”
Dr. James DiRenzo, who will lead this effort added, “Transmission of avian influenza viruses from birds to humans is rare but can cause greater than 40% mortality. Therefore, their continued circulation in diverse bird populations, coupled with their truly alarming rates of mutation and genetic reassortment sharply increases the risk that they acquire the ability to pass directly from one human to another. CM-IAV1 prevents infection of target cells by targeting a conserved region of the virus. This is a highest priority threat that merits significant mitigation and preparedness efforts.”
Research reported in this press release is supported by the National Institute of Allergy and Infectious Disease of the National Institutes of Health under award number 1R44AI157074. The content is solely the responsibility of Celdara Medical and does not necessarily represent the official views of the National Institutes of Health.
About Celdara Medical
Celdara Medical was founded by Drs. Jake Reder and Michael Fanger in 2008, and is headquartered at the Dartmouth Regional Technology Center (DRTC) in Lebanon, NH. Celdara Medical builds academic and early-stage innovations into high-potential medical companies, identifying discoveries of exceptional value at the earliest stages and moving them toward the market. Celdara Medical partners with inventors and their institutions, providing the developmental, financial, and business acumen required to bridge discovery and profitability. With robust funding options, a diverse and high impact Programmatic pipeline, and partnerships with world-class academic institutions and industry leaders, Celdara Medical navigates all aspects of a complex industry, accelerating science to improve human health. Further information about Celdara Medical is available at celdaramedical.com.